The Clinical Relevance of Imatinib Plasma Trough Concentrations in Chronic Myeloid Leukemia. A Belgian Study

Clinical Biochemistry - Netherlands
doi 10.1016/j.clinbiochem.2016.12.006
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Influence of CYP3A5 and Drug Transporter Polymorphisms on Imatinib Trough Concentration and Clinical Response Among Patients With Chronic Phase Chronic Myeloid Leukemia

Journal of Human Genetics
Genetics
2010English

Comparison of Branded and Generic Imatinib Plasma Concentrations in Patients With Chronic Myelogenous Leukemia: Unicentric Study

Clinical Lymphoma, Myeloma and Leukemia
Cancer ResearchOncologyHematology
2016English

Dasatinib in the Treatment of Imatinib Refractory Chronic Myeloid Leukemia

Biologics: Targets and Therapy
OncologyImmunologyGastroenterologyPharmacologyRheumatologyAllergy
2009English

Therapy of Chronic Myeloid Leukemia: Twilight of the Imatinib Era?

ISRN Oncology
2014English

The Development of Imatinib as a Therapeutic Agent for Chronic Myeloid Leukemia

Blood
BiochemistryImmunologyCell BiologyHematology
2005English

Therapeutic Drug Monitoring of Imatinib for Chronic Myeloid Leukemia Patients

2012English

Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: Recommendations for Clinical Practice From the French Chronic Myeloid Leukemia Study Group

Cancer
Cancer ResearchOncology
2018English

Gene Expression Signature of Primary Imatinib-Resistant Chronic Myeloid Leukemia Patients

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2006English

Spred2 Modulates the Erythroid Differentiation Induced by Imatinib in Chronic Myeloid Leukemia Cells

PLoS ONE
Multidisciplinary
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy